Compare EQPT & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQPT | TWST |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | 8206 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | N/A | 2018 |
| Metric | EQPT | TWST |
|---|---|---|
| Price | $19.08 | $98.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $38.88 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 2.3M | 2.1M |
| Earning Date | 03-18-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $21.53 | $18.91 |
| Revenue Next Year | $23.15 | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $17.95 | $23.30 |
| 52 Week High | $35.50 | $105.47 |
| Indicator | EQPT | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 72.21 |
| Support Level | $18.71 | $42.88 |
| Resistance Level | $26.64 | N/A |
| Average True Range (ATR) | 1.71 | 6.09 |
| MACD | -0.33 | 1.20 |
| Stochastic Oscillator | 6.18 | 79.55 |
EquipmentShare.com Inc is a vertically integrated platform that combines proprietary technology, a connected equipment fleet, and a nationwide footprint to serve the construction industry. The company operates its business through the following reportable segments: Equipment Rental and Services Operations, comprised of recurring activity performed at full-service branch locations, such as equipment rentals and related services, and sales of parts, supplies, and maintenance services to construction contractors and others. Equipment Sales, sales of new or used equipment made at any of the branch locations and dealership sites, including equipment sales to participants in the OWN Program.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.